The suppression of immunosuppression within the tumor stroma has been shown to enhance the effectiveness of other therapeutic interventions, underscoring the potential of FAPα-targeted therapy as a promising avenue for enhancing outcomes in patients diagnosed with melanoma. The gene discussed is FAP; the disease is melanoma.